JiangXi Tianxin Pharm Co Ltd (603235) - Total Liabilities
Based on the latest financial reports, JiangXi Tianxin Pharm Co Ltd (603235) has total liabilities worth CN¥1.07 Billion CNY (≈ $157.14 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 603235 cash flow metrics to assess how effectively this company generates cash.
JiangXi Tianxin Pharm Co Ltd - Total Liabilities Trend (2020–2024)
This chart illustrates how JiangXi Tianxin Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check JiangXi Tianxin Pharm Co Ltd (603235) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
JiangXi Tianxin Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of JiangXi Tianxin Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stagwell Inc
NASDAQ:STGW
|
USA | $3.41 Billion |
|
Cosmo Pharmaceuticals N.V
F:C43
|
Germany | €123.46 Million |
|
Almonty Industries Inc. Common Shares
NASDAQ:ALM
|
USA | $261.80 Million |
|
PLUXEE NV
PA:PLX
|
France | €5.93 Billion |
|
Sichuan Furong Technology Co Ltd
SHG:603327
|
China | CN¥1.53 Billion |
|
Cofco Biochemical Anhui Co Ltd
SHE:000930
|
China | CN¥6.09 Billion |
|
Visionox Technology Inc
SHE:002387
|
China | CN¥31.60 Billion |
|
Nuvation Bio Inc
NYSE:NUVB
|
USA | $275.68 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down JiangXi Tianxin Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of JiangXi Tianxin Pharm Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how JiangXi Tianxin Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for JiangXi Tianxin Pharm Co Ltd (2020–2024)
The table below shows the annual total liabilities of JiangXi Tianxin Pharm Co Ltd from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥987.41 Million ≈ $144.49 Million |
+15.19% |
| 2023-12-31 | CN¥857.21 Million ≈ $125.44 Million |
+37.82% |
| 2022-12-31 | CN¥621.98 Million ≈ $91.02 Million |
-40.40% |
| 2021-12-31 | CN¥1.04 Billion ≈ $152.71 Million |
-40.72% |
| 2020-12-31 | CN¥1.76 Billion ≈ $257.61 Million |
-- |
About JiangXi Tianxin Pharm Co Ltd
JiangXi Tianxin Pharmaceutical Co., Ltd. produces and sells vitamins in China. The company offers products of vitamin B6, vitamin B1, Vitamin D3, pyridoxine hydrochloride CD grade, thiamine nitrate DC grade, folic acid, biotin, ascorbyl palmitate, vitamin E 500, a-acetyl-"-butyrolactone, and vitamin D3 for use as bulk pharmaceutical chemicals, API, food additives, and feed additives, as well as i… Read more